Sugi Predict

Sugi Predict / Compounds / SCHEMBL908398

SCHEMBL908398

SCHEMBL908398

Fc1ccc(-c2cc(Cl)nc(Cl)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ L3MBTL1 Q9Y468 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ HPGD P15428 2/20 0.52
▸ KDM4E B2RXH2 6/20 0.47
▸ MAPT P10636 4/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ TXN P10599 1/20 0.46
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ DHODH Q02127 1/20 0.43
▸ RAB9A P51151 2/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ S1PR2 O95136 1/20 0.41
▸ RAD51 Q06609 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10051515 0.91 MEN1 (0.60) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL17679134 0.89 L3MBTL1 (0.64) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL3564907 0.85 ALDH1A1 (0.54) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL21058802 0.82 ALDH1A1 (0.42) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL1644353 0.82 HSP90AA1 (0.68) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL600729 0.82 RAD51 (0.44) MEN1KMT2AALDH1A1L3MBTL1HPGD
SCHEMBL7381830 0.82 MEN1 (0.73) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL3450627 0.82 KDM4E (0.70) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL28252052 0.82 MEN1 (0.80) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL29511675 0.82 MEN1 (0.73) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796673-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-06-20 — — EP claimed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 — — US claimed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 — — WO claimed
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
EP-3362451-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 — — EP disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
CN-114533729-A Glucosylceramide synthase inhibitors 建新公司 2022-05-27 — — CN disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed
CN-108864076-B Glucosylceramide synthase inhibitors 建新公司 2022-02-11 — — CN disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 — — US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 — — US disclosed
WO-2006078992-A2 HETEROARYL SUBSTITUTED PIPERAZINYL-PYRIDINE ANALOGUES NEUROGEN CORPORATION (US) 2006-07-27 — — WO disclosed
US-20060122394-A1 Substituted biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2006-06-08 — — US disclosed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 — — US disclosed
EP-1644358-A2 BIARYL PIPERAZINYL-PYRIDINE ANALOGUES NEUROGEN CORPORATION (US) 2006-04-12 — — EP disclosed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 — — WO disclosed
WO-2006026135-A2 SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES NEUROGEN CORPORATION (US) 2006-03-09 — — WO disclosed
WO-2005007648-A2 BIARYL PIPERAZINYL-PYRIDINE ANALOGUES NEUROGEN CORPORATION (US) 2005-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them UMPS, DPYD, TYMS MEN1 4470/4885KMT2A 4623/4885ALDH1A1 3580/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC MEN1 1781/4885KMT2A 2942/4885ALDH1A1 2066/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA MEN1 1532/4885KMT2A 2721/4885ALDH1A1 2144/4885
US-20060122394-A1 Substituted biaryl piperazinyl-pyridine analogues GPR88, PRLHR, GPR68 MEN1 4733/4885KMT2A 3476/4885ALDH1A1 801/4885
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG MEN1 4708/4885KMT2A 3700/4885ALDH1A1 920/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA MEN1 1532/4885KMT2A 2721/4885ALDH1A1 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.